

# Gene Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/698960/publications.pdf>

Version: 2024-02-01

81  
papers

3,760  
citations

236925

25  
h-index

133252

59  
g-index

81  
all docs

81  
docs citations

81  
times ranked

5592  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined heart-liver-kidney transplant: The university of Chicago medicine experience. <i>Clinical Transplantation</i> , 2022, 36, e14586.	1.6	2
2	A New Strategy for Left Ventricular Assist Device Outflow Graft Interrogation Using Ultrasound Contrast. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 445-447.	2.8	1
3	Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. <i>American Journal of Clinical Pathology</i> , 2021, 155, 793-801.	0.7	15
4	Impact of worsening of aortic insufficiency during HeartMate 3 LVAD support. <i>Artificial Organs</i> , 2021, 45, 297-302.	1.9	14
5	Discordance between immunofluorescence and immunohistochemistry C4d staining and outcomes following heart transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14242.	1.6	2
6	Donor-derived cell-free DNA is associated with cardiac allograft vasculopathy. <i>Clinical Transplantation</i> , 2021, 35, e14206.	1.6	14
7	The Clinical Importance of Hyponatremia in Patients with Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2021, 67, 1012-1017.	1.6	4
8	Incidence and Clinical Significance of Hyperkalemia Following Heart Transplantation. <i>Transplantation Proceedings</i> , 2021, 53, 673-680.	0.6	1
9	Editorial: A call to action: let's work together to end racial disparities in heart failure. <i>Current Opinion in Cardiology</i> , 2021, 36, 318-319.	1.8	0
10	Outcomes of Ambulatory Axillary Intraaortic Balloon Pump as a Bridge to Heart Transplantation. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1264-1270.	1.3	22
11	Oral Milrinone for the Treatment of Chronic Severe Right Ventricular Failure in Left Ventricular Assist Device Patients. <i>Circulation: Heart Failure</i> , 2021, 14, e007286.	3.9	7
12	Impact of Race on Clinical Outcomes After Implantation With a Fully Magnetically Levitated Left Ventricular Assist Device: An Analysis From the MOMENTUM 3 Trial. <i>Circulation: Heart Failure</i> , 2021, 14, e008360.	3.9	9
13	Outcomes From Three Decades of Infant and Pediatric Heart Transplantation. <i>ASAIO Journal</i> , 2021, 67, 1051-1059.	1.6	8
14	Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 271-278.	1.5	4
15	Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2020, 66, 253-257.	1.6	5
16	Hemodynamic Effects of Concomitant Mitral Valve Surgery and Left Ventricular Assist Device Implantation. <i>ASAIO Journal</i> , 2020, 66, 355-361.	1.6	9
17	Estimation of the Severity of Aortic Insufficiency by HVAD Flow Waveform. <i>Annals of Thoracic Surgery</i> , 2020, 109, 945-949.	1.3	5
18	Estimation of Central Venous Pressure by Pacemaker Lead Impedances in Left Ventricular Assist Device Patients. <i>ASAIO Journal</i> , 2020, 66, 49-54.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Omega-3 and hemocompatibility-related adverse events. <i>Journal of Cardiac Surgery</i> , 2020, 35, 405-412.	0.7	4
20	Heart transplantation in patients with localized prostate cancer—Are we denying a life-saving therapy due to an indolent tumor?. <i>Clinical Transplantation</i> , 2020, 34, e14080.	1.6	2
21	Hypogammaglobulinemia following heart transplantation: Prevalence, predictors, and clinical importance. <i>Clinical Transplantation</i> , 2020, 34, e14087.	1.6	3
22	Neurohormonal Blockade During Left Ventricular Assist Device Support. <i>ASAIO Journal</i> , 2020, 66, 881-885.	1.6	4
23	CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy. <i>JACC: CardioOncology</i> , 2020, 2, 515-518.	4.0	5
24	Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options. <i>American Journal of Transplantation</i> , 2020, 20, 2916-2922.	4.7	41
25	Aortic Insufficiency During HeartMate 3 Left Ventricular Assist Device Support. <i>Journal of Cardiac Failure</i> , 2020, 26, 863-869.	1.7	18
26	Decoupling Between Diastolic Pulmonary Artery and Pulmonary Capillary Wedge Pressures Is Associated With Right Ventricular Dysfunction and Hemocompatibility-Related Adverse Events in Patients With Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2020, 9, e014801.	3.7	10
27	Massive Myocardial Calcium Deposition. <i>JACC: Case Reports</i> , 2020, 2, 996-1003.	0.6	2
28	Transcatheter Aortic Valve Replacement in Left Ventricular Assist Device Patients with Aortic Regurgitation. <i>Structural Heart</i> , 2020, 4, 107-112.	0.6	8
29	Optimal cannula positioning of HeartMate 3 left ventricular assist device. <i>Artificial Organs</i> , 2020, 44, e509-e519.	1.9	4
30	HeartWare Ventricular Assist Device Cannula Position and Hemocompatibility-Related Adverse Events. <i>Annals of Thoracic Surgery</i> , 2020, 110, 911-917.	1.3	6
31	Longitudinal Trajectories of Hemodynamics Following Left Ventricular Assist Device Implantation. <i>Journal of Cardiac Failure</i> , 2020, 26, 383-390.	1.7	13
32	Effect of Concomitant Tricuspid Valve Surgery With Left Ventricular Assist Device Implantation. <i>Annals of Thoracic Surgery</i> , 2020, 110, 918-924.	1.3	13
33	Combined Left Ventricular Assist Device and Coronary Artery Bypass Grafting Surgery: Should We Bypass the Bypass?. <i>ASAIO Journal</i> , 2020, 66, 32-37.	1.6	8
34	HVAD Flow Waveform Estimates Left Ventricular Filling Pressure. <i>Journal of Cardiac Failure</i> , 2020, 26, 342-348.	1.7	8
35	Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent. <i>JAMA Cardiology</i> , 2020, 5, 411.	6.1	109
36	Deep Y-Descent in Right Atrial Waveforms Following Left Ventricular Assist Device Implantation. <i>Journal of Cardiac Failure</i> , 2020, 26, 360-367.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Outcomes following left ventricular assist device exchange. <i>Journal of Cardiac Surgery</i> , 2020, 35, 591-597.	0.7	4
38	Molecular Mechanism of the Association Between Atrial Fibrillation and Heart Failure Includes Energy Metabolic Dysregulation Due to Mitochondrial Dysfunction. <i>Journal of Cardiac Failure</i> , 2019, 25, 911-920.	1.7	33
39	Left Atrial Appendage Occlusion With Left Ventricular Assist Device Decreases Thromboembolic Events. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1181-1186.	1.3	19
40	Optimal Hemodynamics During Left Ventricular Assist Device Support Are Associated With Reduced Readmission Rates. <i>Circulation: Heart Failure</i> , 2019, 12, e005094.	3.9	71
41	Impact of Hemodynamic Ramp Test-Guided HVAD Speed and Medication Adjustments on Clinical Outcomes. <i>Circulation: Heart Failure</i> , 2019, 12, e006067.	3.9	60
42	Increasing heart transplant donor pool by liberalization of size matching. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1197-1205.	0.6	19
43	Aortic Insufficiency and Hemocompatibility-related Adverse Events in Patients with Left Ventricular Assist Devices. <i>Journal of Cardiac Failure</i> , 2019, 25, 787-794.	1.7	13
44	Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 997-999.	0.6	9
45	Hemodynamics of concomitant tricuspid valve procedures at LVAD implantation. <i>Journal of Cardiac Surgery</i> , 2019, 34, 1511-1518.	0.7	7
46	Association of Inflow Cannula Position with Left Ventricular Unloading and Clinical Outcomes in Patients with HeartMate II Left Ventricular Assist Device. <i>ASAIO Journal</i> , 2019, 65, 331-335.	1.6	30
47	Optimal haemodynamics during left ventricular assist device support are associated with reduced haemocompatibility-related adverse events. <i>European Journal of Heart Failure</i> , 2019, 21, 655-662.	7.1	72
48	Improvement in Biventricular Cardiac Function After Ambulatory Counterpulsation. <i>Journal of Cardiac Failure</i> , 2019, 25, 20-26.	1.7	9
49	Consequences of Retained Defibrillator and Pacemaker Leads After Heart Transplantation—An Underrecognized Problem. <i>Journal of Cardiac Failure</i> , 2018, 24, 101-108.	1.7	12
50	Long-Acting Octreotide Reduces the Recurrence of Gastrointestinal Bleeding in Patients With a Continuous-Flow Left Ventricular Assist Device. <i>Journal of Cardiac Failure</i> , 2018, 24, 249-254.	1.7	31
51	Increased Risk of Bleeding in Left Ventricular Assist Device Patients Treated with Enoxaparin as Bridge to Therapeutic International Normalized Ratio. <i>ASAIO Journal</i> , 2018, 64, 140-146.	1.6	18
52	Cannula and Pump Positions Are Associated With Left Ventricular Unloading and Clinical Outcome in Patients With HeartWare Left Ventricular Assist Device. <i>Journal of Cardiac Failure</i> , 2018, 24, 159-166.	1.7	23
53	Repeated Ramp Tests on Stable LVAD Patients Reveal Patient-Specific Hemodynamic Fingerprint. <i>ASAIO Journal</i> , 2018, 64, 701-707.	1.6	11
54	The first-in-human experience with a minimally invasive, ambulatory, counterpulsation heart assist system for advanced congestive heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1-6.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Analysis of Patients with Ventricular Assist Devices Presenting to an Urban Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2018, 19, 907-911.	1.1	9
56	Omega-3 Therapy Is Associated With Reduced Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device. <i>Circulation: Heart Failure</i> , 2018, 11, e005082.	3.9	51
57	Decoupling Between Diastolic Pulmonary Arterial Pressure and Pulmonary Arterial Wedge Pressure at Incremental Left Ventricular Assist Device (LVAD) Speeds Is Associated With Worse Prognosis After LVAD Implantation. <i>Journal of Cardiac Failure</i> , 2018, 24, 575-582.	1.7	19
58	The Effect of Left Ventricular Assist Device Therapy on Cardiac Biomarkers: Implications for the Identification of Myocardial Recovery. <i>Current Heart Failure Reports</i> , 2018, 15, 250-259.	3.3	13
59	Residual native left ventricular function optimization using quantitative 3D echocardiographic assessment of rotational mechanics in patients with left ventricular assist devices. <i>Echocardiography</i> , 2018, 35, 1606-1615.	0.9	6
60	Predictors of Hemodynamic Improvement and Stabilization Following Intraaortic Balloon Pump Implantation in Patients With Advanced Heart Failure. <i>Journal of Invasive Cardiology</i> , 2018, 30, 56-61.	0.4	12
61	Complementary roles of gasotransmitters CO and H <sub>2</sub> S in sleep apnea. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1413-1418.	7.1	65
62	Atrial Arrhythmias and Electroanatomical Remodeling in Patients With Left Ventricular Assist Devices. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	37
63	Cardiac Output Assessment in Patients Supported with Left Ventricular Assist Device: Discordance Between Thermodilution and Indirect Fick Cardiac Output Measurements. <i>ASAIO Journal</i> , 2017, 63, 433-437.	1.6	12
64	Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure as a Prognostic Factor After Continuous Flow Ventricular Assist Device Implantation. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	57
65	Myocardial Recovery After LVAD Implantation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 355-357.	2.8	12
66	Surgically Corrected Mitral Regurgitation During Left Ventricular Assist Device Implantation Is Associated With Low Recurrence Rate and Improved Midterm Survival. <i>Annals of Thoracic Surgery</i> , 2017, 103, 725-733.	1.3	36
67	Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H962-H972.	3.2	114
68	LMO7 <sup>kn</sup> null mice exhibit phenotypes consistent with emery-dereifuss muscular dystrophy. <i>Muscle and Nerve</i> , 2015, 51, 222-228.	2.2	17
69	Cardiac function in muscular dystrophy associates with abdominal muscle pathology. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 39-49.	2.6	11
70	Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. <i>Nature Communications</i> , 2015, 6, 6656.	12.8	336
71	The Subclavian Intraaortic Balloon Pump: A Compelling Bridge Device for Advanced Heart Failure. <i>Annals of Thoracic Surgery</i> , 2015, 100, 2151-2158.	1.3	64
72	<i>Abcc9</i> is required for the transition to oxidative metabolism in the newborn heart. <i>FASEB Journal</i> , 2014, 28, 2804-2815.	0.5	16

#	ARTICLE	IF	CITATIONS
73	Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. <i>Atherosclerosis</i> , 2013, 228, 69-79.	0.8	46
74	Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H415-H426.	3.2	74
75	The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. <i>Nature Medicine</i> , 2012, 18, 1643-1650.	30.7	400
76	Vascular Remodeling and Arterial Calcification Are Directly Mediated by S100A12 (EN-RAGE) in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2011, 33, 250-259.	3.1	55
77	S100A12 in Vascular Smooth Muscle Accelerates Vascular Calcification in Apolipoprotein E Null Mice by Activating an Osteogenic Gene Regulatory Program. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 337-344.	2.4	97
78	S100A12 Mediates Aortic Wall Remodeling and Aortic Aneurysm. <i>Circulation Research</i> , 2010, 106, 145-154.	4.5	79
79	Exogenous NAD Blocks Cardiac Hypertrophic Response via Activation of the SIRT3-LKB1-AMP-activated Kinase Pathway. <i>Journal of Biological Chemistry</i> , 2010, 285, 3133-3144.	3.4	351
80	Nesprin-1 mutations in human and murine cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 600-608.	1.9	124
81	Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 2758-71.	8.2	781